ZEB1 and non-small cell lung carcinoma: To ascertain the significance of these ZEB1 interactors as therapeutic targets in metastatic NSCLC we utilized a previously published in vivo shRNA drop out screen methodology specifically concentrated on epigenetic regulators23.